Core Viewpoint - MIRXES-B has established a strategic partnership with Yunnan Watson Biotechnology to create an RNA-centered prevention and precision medicine platform, enhancing their capabilities in clinical trials, registration, and sales [1] Group 1: Partnership Details - The memorandum of understanding (MOU) between MIRXES and Watson is valid for two years from the signing date [1] - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1] Group 2: Technological and Operational Synergies - MIRXES will integrate its advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's mRNA vaccine technology [1] - The partnership will utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1] - The collaboration is expected to enhance both companies' research and commercial deployment capabilities in the field of prevention and precision medicine [1]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 5% in the afternoon trading session, with a current price of 52.55 HKD and a trading volume of 32.73 million HKD. The company has entered into a memorandum of understanding with Yunnan Watson Bio (300142) to establish a strategic partnership focused on RNA-based preventive and precision medicine [1]. Group 1 - The memorandum of understanding is set for a duration of two years from the date of signing [1]. - The collaboration aims to leverage the complementary strengths of both companies, creating synergies in their operations [1]. - The partnership will integrate MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and robust clinical pipeline [1]. Group 2 - The strategic partnership will encompass joint development, clinical trials, registration, as well as sales and distribution [1]. - The collaboration is expected to establish a comprehensive platform for research and commercial deployment in preventive and precision medicine [1]. - The partnership will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base [1].

Core Viewpoint - MIRXES-B (02629) has entered into a memorandum of understanding with Yunnan Watson Biotechnology to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to create synergies [1] Group 2: Technological and Operational Synergies - The partnership will combine MIRXES's advanced RNA diagnostic technology and proprietary Asia-centric disease RNA database with Watson's proprietary mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Objectives - The partnership will create synergies by combining MIRXES's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] - The collaboration will also utilize MIRXES's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1]

Core Viewpoint - MIRXES-B (02629.HK) has signed a memorandum of understanding with Watson Bio (300142.SZ) to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1] Group 1: Partnership Details - The memorandum of understanding is effective for two years from the date of signing [1] - The collaboration aims to leverage the complementary strengths of both companies to advance early detection and preventive medicine, aligning with their long-term goals [1] Group 2: Strategic Implications - This partnership signifies a significant transformation for the company, moving from early detection to prevention and precision medicine [1] - The collaboration is expected to create synergies by combining the company's advanced RNA diagnostic technology and proprietary disease RNA database with Watson's mRNA vaccine technology and strong clinical pipeline [1] Group 3: Operational Capabilities - The partnership will utilize the company's production and regulatory capabilities in the ASEAN region, including the first Industry 4.0 nucleic acid testing and reagent production base in the area [1] - The collaboration will also enhance distribution channels within ASEAN, integrating research and commercial deployment into a cohesive prevention and precision medicine platform [1]